News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly News from the ORION programme with inclisiran: ORION-2, ORION-3 Phase 2 data with novel adnectin PCSK9 inhibitor LIB003 Screening for FH paramount to avoid early loss of life VESALIUS-CV ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Slide decks focusing on key results and expert analysis from FOURIER and ODYSSEY OUTCOMES – two landmark trials in PCSK9 inhibition.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

News from the 87th European Atherosclerosis Society Congress

News from ORION-2, ORION-3 with inclisiran

Novel PCSK9 adnectin LIB003 looks good

Screening for FH helps prevent early death

ACC Scientific Sessions 2019

What was the PCSK9 news at this year’s Congress?

ODYSSEY OUTCOMES: Lipoprotein(a) analysis

More insights from ODYSSEY OUTCOMES

Most viewed

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) VIDEO: New insights from ODYSSEY OUTCOMES Who is receiving PCSK9 inhibitors in the real world? VESALIUS-CV: New outcomes study with evolocumab VESALIUS-CV Phase 2 data with novel adnectin PCSK9 inhibitor LIB003 VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study Cost remains the issue for use of PCSK9 inhibitors ACC 2015 More safety data with PCSK9 inhibitors: patients with very low LDL-C PCSK9 Forum Inhibitors and Health Economics

Most viewed

VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a)

Hot Topics

Coronary artery calcium in familial hypercholesterolaemia

Coronary artery calcium may have a role in stratifying short-term risk in patients with familial hypercholesterolaemia (FH, inherited high cholesterol), according to a new study. This noninvasive approach may have value in targeting treatment with a PCSK9 inhibitor to those patients at highest risk.
Read the report

VIDEO: Is coronary artery calcium a risk assessment too in FH?
Watch the video

VIDEO: Severe FH: how to define?
Watch the video

VIDEO: ESC/EAS Task Force guidance for PCSK9 inhibitors
Watch the video

From the Editors

New US Cholesterol Guidelines: The good, the bad and the ugly

PCSK9 Forum Editor Professor Professor Henry Ginsberg (Columbia University, New York, USA) discusses how the new guidelines might be viewed as a remake of the great spaghetti western called “The Good, the Bad, and the Ugly.”
Read the report

Video: AHA 2018 US Cholesterol Guidelines